Le Lézard
Classified in: Health
Subjects: SVY, TRI

Shoulder Innovation Announces Publication Of Long Term Data For Insettm Glenoid


HOLLAND, Mich., April 18, 2019 /PRNewswire/ -- Genesis Innovation Group's Shoulder Innovations (SI) is focused on human centered design.  Stephen Gunther, M.D., from Charlottesville, VA and the team at Shoulder Innovations have developed an innovative solution for the glenoid, called the InSettm Glenoid, which simplifies the surgical technique for surgeons, minimizes the instrumentation handled by OR staff and improves fixation and surgical outcomes for patients. 

Shoulder Innovations company logo (PRNewsfoto/Shoulder Innovations)

The impressive results of Dr. Gunther's work can now be found in the latest Journal of Shoulder and Elbow Surgery (JSES), the peer-reviewed official publication for eight leading specialty organizations.  In the group of study patients presented, all subjects treated had challenging C-type glenoids, with severely deficient bone.  In the 9+ years follow-up there were no revision surgeries, surgical complications or infections reported.  In the patients presenting for follow-up, there was no evidence of glenoid loosening. 

David Blue, Chief Commercial Officer of Shoulder Innovations, said, "Dr. Gunther has diligently studied and developed the InSet product and technique providing for the opportunity for improved patient outcomes.  This recent publication provides a very encouraging data set supportive of Dr. Gunther's original concepts.  Together with a world class group of surgeons, Shoulder Innovations has already further improved the product and technique so that the technology can be available to a broader patient population."

Shoulder Innovations' customer base has embraced the InSet Glenoid technology wholeheartedly in the past 24 months leading to 1,000 glenoid surgical cases. The company now also offers the FDA cleared InSet Short Stem Humeral component as part of the InSet Total Shoulder System.

Rob Ball, Executive Chairman of Shoulder Innovations said, "Shoulder Innovations' passion has been to deeply engage shoulder specialists in the development of innovative shoulder products that will pave the way for the future. The primary focused goal for SI is to provide improved treatment of patients, with higher reliability of outcomes, at a lower cost, while providing simpler implantation than existing methods.  We've used a rigorous risk-based approach to achieve these goals, and the results speak for themselves."

For more information on Shoulder Innovations, visit www.shoulderinnovations.com

SOURCE Shoulder Innovations


These press releases may also interest you

at 09:38
The Wyatt Foundation and The Conceive Fertility Foundation announce today a joint partnership that will award $15,000 grants to five individuals/couples who need in vitro fertility (IVF) to build their families. Launching during National Infertility...

at 09:38
New platform and surgery center investment adds advanced facility capabilities to specialty care network, strengthening in-person treatment and attracting leading orthopedic surgeons and physiciansWith Theater launch, value-based MSK care visionary...

at 09:34
The below resolutions were passed at Medicover's annual general meeting (the "AGM") held today on 26 April 2024. Election of the board of directors and auditor The AGM resolved, in accordance with the proposal from the nomination committee, that the...

at 09:00
Dental Care Acworth is thrilled to utilize this remarkable innovation and offer patients unbiased, objective and standardized dental care that they know they can trust. The AI solutions Pearl delivers can assist dental...

at 09:00
Tolland Hill Family Dental is thrilled to announce the addition of Dr. Conway Ma to its esteemed team of dental professionals. Tolland Hill Family Dental offers a wide range of services, catering to patients of all ages. From a child's first dental...

at 09:00
Amgen today announced the imminent submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for teprotumumab, a fully human monoclonal antibody and targeted inhibitor of the insulin-like growth factor-1...



News published on and distributed by: